A5007430480- Diabetes and associated disorders
- Pancreatic function and diabetes
- Diabetes Management and Research
- Probiotics and Fermented Foods
- Oral health in cancer treatment
- Gut microbiota and health
- Pharmacological Effects of Natural Compounds
- Cancer Research and Treatments
- Microbial Metabolites in Food Biotechnology
- Polyomavirus and related diseases
- Digestive system and related health
- Infant Nutrition and Health
- Neuropeptides and Animal Physiology
- Diet, Metabolism, and Disease
- Immune Cell Function and Interaction
- Pneumocystis jirovecii pneumonia detection and treatment
ActoGeniX (Belgium)
2009-2015
VIB-UGent Center for Medical Biotechnology
2006
Current interventions for arresting autoimmune diabetes have yet to strike the balance between sufficient efficacy, minimal side effects, and lack of generalized immunosuppression. Introduction antigen via gut represents an appealing method induction antigen-specific tolerance. Here, we developed a strategy tolerance restoration using mucosal delivery in mice biologically contained Lactococcus lactis genetically modified secrete whole proinsulin autoantigen along with immunomodulatory...
Growing insight into the pathogenesis of type 1 diabetes (T1D) and numerous studies in preclinical models highlight potential antigen-specific approaches to restore tolerance efficiently safely. Oral administration protein antigens is a preferred method for induction, but degradation during gastrointestinal passage can impede such protein-based therapies, reducing their efficacy making them cost-ineffective. To overcome these limitations, we generated tolerogenic bacterial delivery...
Abstract Aims/hypothesis We hypothesised that islet beta cell antigen presentation in the gut along with a tolerising cytokine would lead to antigen-specific tolerance type 1 diabetes. evaluated this parallel open-label Phase 1b study using oral AG019, food-grade Lactococcus lactis bacteria genetically modified express human proinsulin and IL-10, as monotherapy parallel, randomised, double-blind 2a AG019 combination teplizumab. Methods Adults (18–42 years) adolescents (12–17 diabetes...
A combination treatment (CT) of proinsulin and IL-10 orally delivered via genetically modified Lactococcus lactis bacteria combined with low-dose anti-CD3 (aCD3) therapy successfully restores glucose homeostasis in newly diagnosed non-obese diabetic (NOD) mice. Tolerance is accompanied by the accumulation Foxp3+ regulatory T cells (Tregs) pancreas. To test potential this outside window acute diabetes diagnosis, we substituted autoimmune mice, disease durations varying between 4 53 days,...
Type 1 diabetes (T1D) is a chronic autoimmune disease characterised by excessive immune reactions against auto-antigens of pancreatic β-cells. Restoring auto-antigen tolerance remains the superior therapeutic strategy. Oral administration uses tolerogenic nature gut-associated system to induce antigen-specific tolerance. However, due gastric degradation, proper mucosal product delivery often imposes challenge. Recombinant Lactococcus lactis have proven be effective and safe carriers for...
Chemotherapy-induced intestinal injury, referred to as mucositis, is a major side effect of cancer therapy. At the moment, there are no agents available that prevent or heal damage and this limits both dose duration treatment. Trefoil factor 3 (TFF3) present in small large intestine thought play role tissue protection healing after injury. TFF3 may also modulate response cytotoxic like 5-fluorouracil (5FU). We previously demonstrated oral administration secreting Lactococcus lactis (LL)...